What Is Liquid Biopsy and How It Helps Detect Cancer Early

Table of Contents

• What Is Liquid Biopsy?
• Understanding Liquid Biopsy: How It Works
• Liquid Biopsy vs Traditional Biopsy
• When and Why Liquid Biopsy Is Used
• Liquid Biopsy for Lung Cancer
• FDA-Approved Liquid Biopsy Tests
• Liquid Biopsy Procedure: What to Expect
• Liquid Biopsy Cost: What You Should Know
• Benefits and Limitations of Liquid Biopsy
• Conclusion: The Role of Liquid Biopsy in Early Cancer Detection
• FAQs

What Is Liquid Biopsy?

Early cancer detection plays a critical role in improving treatment outcomes and survival rates. Traditionally, diagnosing cancer required invasive tissue biopsies, which may not always be feasible or safe. This is where liquid biopsy has emerged as a breakthrough diagnostic approach.

A liquid biopsy is a blood test that detects cancer by identifying tumour-related material circulating in the bloodstream. It offers a minimally invasive way to gather valuable information about cancer presence, progression, and genetic characteristics often helping doctors make informed treatment decisions earlier.

Understanding Liquid Biopsy: How It Works

Unlike traditional biopsies that require tissue removal, liquid biopsy analyses blood samples to detect cancer-related fragments released by tumours. These fragments carry important genetic information that helps identify cancer type and behaviour.

Key Components Detected in Liquid Biopsy

• Circulating Tumour Cells (CTCs):
  These are intact cancer cells that break away from the original tumour and travel through the bloodstream. Higher CTC counts are often associated with advanced disease or poorer prognosis.
• Circulating Tumour DNA (ctDNA):
  These are small DNA fragments released when cancer cells die. ctDNA carries genetic mutations that can reveal the cancer’s molecular profile.

By analysing these components, doctors can identify the presence of cancer and understand how it may respond to specific therapies.

Liquid Biopsy vs Traditional Biopsy

While both tests aim to diagnose and monitor cancer, they differ significantly in approach and application.

Although tissue biopsy remains the gold standard for initial cancer diagnosis, liquid biopsy provides valuable insights when tissue sampling is difficult, risky, or not possible.

When and Why Liquid Biopsy Is Used

Liquid biopsy is especially useful in specific clinical scenarios:

Advanced or Metastatic Cancer

In advanced cancer cases where the disease has spread, repeated tissue biopsies may be impractical. Liquid biopsy allows ongoing monitoring without additional invasive procedures.

Treatment Monitoring and Prognosis

Changes in ctDNA or CTC levels can indicate how well a treatment is working. Decreasing levels suggest a positive response, while increasing levels may signal treatment resistance.

Targeted Therapy Selection

By identifying specific genetic mutations, liquid biopsy helps doctors select therapies that directly target those molecular changes, improving treatment precision.

Patients Unsuitable for Surgery

For individuals who are medically unfit for surgery or whose tumours are located in hard-to-reach areas, liquid biopsy offers a safer alternative.

Liquid Biopsy for Lung Cancer

One of the most established uses of this technology is liquid biopsy lung cancer testing. In non-small cell lung cancer (NSCLC), liquid biopsy is used to detect genetic mutations such as EGFR, which guide targeted therapy decisions.

FDA-approved tests like cobas® EGFR Mutation Test v2 allow mutation detection through blood samples, helping doctors determine the most effective treatment without repeated tissue biopsies.

This approach is particularly valuable when lung tumours are difficult to access or when rapid treatment decisions are required.

FDA-Approved Liquid Biopsy Tests

Several validated tests are currently used in clinical practice:

• CellSearch® System:
  Measures circulating tumour cells in breast, prostate, and colorectal cancers to predict outcomes.
• cobas® EGFR Mutation Test v2:
  Identifies EGFR mutations in lung cancer patients.
• Guardant360® CDx:
  Analyses ctDNA to detect mutations across multiple cancer types.
• FoundationOne® Liquid CDx:
  Provides comprehensive genomic profiling to support targeted cancer therapy decisions.

These tests enhance precision oncology by offering genetic insights that guide personalised treatment.

Liquid Biopsy Procedure: What to Expect

The liquid biopsy procedure is straightforward and similar to a routine blood test.

Step-by-Step Process

1. A blood sample is drawn from a vein in the arm.
2. The laboratory separates plasma from blood cells.
3. Advanced molecular testing is performed to detect ctDNA or CTCs.

Patient Experience

• Minimal discomfort
• No recovery time
• No surgical risks

Timeline for Results

Results typically take two to three weeks, depending on the complexity of the genetic analysis.

Understanding the Results

• Positive result: Tumour fragments or mutations detected
• Negative result: No detectable tumour material at the time of testing

A positive result often provides actionable insights but may still require confirmation through a traditional biopsy.

Liquid Biopsy Cost: What You Should Know

The liquid biopsy cost can vary based on several factors, including the type of test, the cancer being evaluated, and the number of genes analysed.

Factors Affecting Cost

• Type of cancer (e.g., liquid biopsy lung cancer)
• Extent of genetic profiling
• Technology used
• Laboratory infrastructure

The cost of liquid biopsy is generally higher than routine blood tests, but it may reduce overall expenses by avoiding invasive procedures, hospital stays, or repeated tissue biopsies.

Patients are advised to consult diagnostic centres directly for accurate pricing and insurance coverage details.

Benefits and Limitations of Liquid Biopsy

Benefits

• Minimally invasive
• Enables early cancer detection
• Allows real-time treatment monitoring
• Supports personalised medicine

Limitations

• May not detect cancer in early or low-tumour-burden cases
• Negative results do not always rule out cancer
• Often used alongside, not instead of, tissue biopsy

Understanding both strengths and limitations ensures realistic expectations from testing.

Conclusion: The Role of Liquid Biopsy in Early Cancer Detection

Liquid biopsy represents a significant advancement in cancer diagnostics, offering a safer and less invasive way to detect and monitor cancer. From identifying genetic mutations to supporting targeted therapy decisions, it plays a vital role in modern oncology care.

While it does not replace traditional biopsies, it complements them—especially in advanced cancers, treatment monitoring, and cases where tissue sampling is challenging.

For advanced cancer diagnostics and expert guidance, Apollo Diagnostics offers state-of-the-art liquid biopsy testing with accurate reporting and clinical support to help guide early detection and personalised treatment decisions.

FAQs

What is a liquid biopsy?
It is a blood test that detects cancer by identifying tumour cells or DNA fragments circulating in the bloodstream.

Is liquid biopsy reliable for cancer diagnosis?
It is reliable for detecting genetic mutations and monitoring cancer, but it does not fully replace tissue biopsy for initial diagnosis.

How long does a liquid biopsy procedure take?
The blood draw takes only a few minutes, similar to a routine blood test.

Is a liquid biopsy painful?
No, it involves minimal discomfort comparable to standard blood collection.

What is the cost of a liquid biopsy?
The cost varies depending on test type and cancer being evaluated. It is best confirmed with a diagnostic centre.

Can a liquid biopsy detect cancer early?
Yes, in some cases, it can detect cancer-related changes earlier and help guide timely treatment decisions